Anti-HIV activity of amphotericin B-cholesteryl sulfate colloidal dispersion in vitro

Antiviral Research

Volumn 42, Issue 3, 1999, Pages

  Konopka, Krystyna ^a   Guo, Luke S S ^b   Düzgüneş, Nejat ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b ALZA CORPORATION   (United States)

Author keywords

Amphotericin B; Amphotericin B colloidal dispersion; Antivirals; Human immunodeficiency virus (HIV); Liposomes; Sterically stabilized liposomes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LIPOSOME;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; SUSPENSION;

AMPHOTERICIN B; ANTI-HIV AGENTS; CHOLESTEROL ESTERS; COLLOIDS; DRUG CARRIERS; GIANT CELLS; HIV-1; HUMANS; LIPOSOMES; TUMOR CELLS, CULTURED;

EID: 0344242137     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00028-5     Document Type: Conference Paper

References (56)

1. Aloia R.C., Tian H., Jensen F.C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. USA. 90:1993;5181-5185.
2. Anaissie E.J., Mattiuzzo G.N., Miller C.B., Noskin G.A., Gurwith M.J., Mamelok R.D., Pietrelli L.A. Treatment of invasive fungal infections in renally impaired patients with Amphotericin B colloidal dispersion. Antimicrob. Agents Chemother. 42:1998;606-611.
3. Baba M., Schols D., Pauwels R., Nakashima H., De Clercq E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy. J. Acquir. Immun. Defic. Syndr. 3:1990;493-499.
4. n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res. 18:1992;191-207.
5. Berger E.A., Clouse K.A., Chaudhary V.K., Chakrabarti S., FitzGerald D.J., Pastan I., Moss B. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc. Natl. Acad. Sci. USA. 86:1989;9539-9543.
6. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta. 864:1986;257-304.
7. Brajtburg J., Elberg S., Bolard J., Kobayashi G.S., Levy R.A., Ostlund R.E. Jr., Schlessinger D., Medoff G. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149:1984;986-997.
8. Callebaut C., Jacotot E., Krust B., Hovanessian A.G. CD26 antigen and HIV fusion? (Response). Science. 264:1994;1162-1165.
9. + cells. AIDS. 5:1991;1453-1461.
10. Coker R.J., Viviani M., Gazzard B.G., Du Pont B., Pohle H.D., Murphy S.M., Atouguia J., Champalimaud J.L., Harris J.R. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 7:1993;829-835.
11. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G.B., Pempinello R., Scott S., Raimondi F., Cascio A., Prestileo T., Caldeira L., Wilkinson R.J., Bryceson A.D.M. Liposomal amphotericin B (Ambisome) in Mediterranean visceral leismaniasis: a multi-centre trial. Q. J. Med. 87:1994;75-81.
12. De Clercq E., Yamamoto N., Pauwels R., Baba M., Schols D., Nakashima H., Balzarini J., Murrer B.A., Schwartz D., Thornton D., Bridger G., Fricker S., Henson G., Abrams M., Picker D. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA. 89:1992;5286-5290.
13. De Vreese K., Reymen D., Griffin P., Steinkasserer A., Werner G., Bridger G.J., Este J., James W., Henson G.E., Desmyter J., Anne J., De Clercq E. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res. 29:1996;209-219.
14. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4:1998;72-77.
15. Edmonds L.C., Davidson L., Bertino J.S. Jr. Solubility and stability of amphotericin B in human serum. Ther. Drug Monit. 11:1989;323-326.
16. Fields R.D., Lancaster M.V. Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am. Biotechnol. Lab. 11:1993;48-50.
17. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:1990;308-329.
18. Guo L.S.S., Fielding R.M., Lasic D.D., Hamilton R.L., Mufson D. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75:1991;45-54.
19. Guo L.S.S., Working P.K. Complexes of Amphotericin B and cholesteryl sulfate. J. Liposome Res. 3:1993;473-490.
20. Hansen J.E., Witzke N.M., Nielsen C., Mathiesen L.R., Teglbjaerg L.S., Nielsen C.M., Nielsen J.O. Derivatives of amphotericin inhibit infection with human immunodeficiency virus in vitro by different modes of action. Antiviral Res. 14:1990;149-159.
21. Hansen J.E., Nielsen C., Svenningsen A., Witzke N., Mathiesen L.R. Synergistic antiviral effect in vitro of azidothymidine and amphotericin B methyl ester in combination on HIV infection. Scand. J. Infect. Dis. 24:1992;35-39.
22. Hanson L.H., Stevens D.A. Comparison of antifungal activity of amphotericin B deoxycholate with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 36:1992;486-488.
23. Hartsel S.C., Hatch C., Ayenew W. How does amphotericin B work?: Studies on model membrane systems. J. Liposome Res. 3:1993;377-408.
24. Hiemenz J.W., Walsh T.J. Lipid formulations of Amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22:1996;S133-S144.
25. Jordan G.W., Humpreys S., Zee Y.C. Effect of amphotericin B methyl ester on vesicular stomatitis virus morphology. Antimicrob. Agents Chemother. 13:1978;340-341.
26. Jordan G.W., Seet E.C. Antiviral effects of amphotericin B methyl ester. Antimicrob. Agents Chemother. 13:1978;199-204.
27. Kataoka T., Koprowski H. Lipids and cell fusion in vitro: effect of amphotericin B. Proc. Soc. Exp. Biol. Med. 149:1975;447-451.
28. Kohno S., Otsubo T., Tanaka E., Maruyama K., Hara K. Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious disease. Adv. Drug Deliv. Rev. 24:1997;325-329.
29. Konopka K., Pretzer E., Celada F., Düzgüneş N. A monoclonal antibody to the gp120-CD4 complex has differential effects on HIV-induced syncytium formation and viral infectivity. J. Gen. Virol. 76:1995;669-679.
30. Konopka K., Pretzer E., Felgner P.L., Düzgüneş N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim. Biophys. Acta. 1312:1996;186-196.
31. Konopka K., Guo L.S.S., Düzgüneş N. Incorporation of amphotericin B into stealth liposomes or colloidal dispersions diminishes its in vitro anti-HIV activity. Antiviral Res. 37:1998;63.
32. Lifson J.D. Fusion of HIV-infected cells with uninfected cells; CD4-dependent HIV-induced cell fusion. Düzgüneş N. Membrane Fusion Techniques, Methods in Enzymology, Vol. 221. 221:1993;3-12 Academic Press, New York.
33. Lopez-Berestein G., Mehta R., Hopfer R.L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E.M., Juliano R.L. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 147:1983;939-945.
34. Magierowska-Jung M., Cefai D., Marrakchi H., Chieze F., Agut H., Huraux J.-M., Seman M. In vitro determination of antiviral activity of MS8209, a new amphotericin B derivative, against primary isolates of HIV. Res. Virol. 147:1996;313-318.
35. McKnight A, Clapham P.R., Weiss R. HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restriction to replication at distinct stages. Virology. 201:1994;8-18.
36. Medoff G., Brajtburg J., Kobayashi G.S., Bolard J. Antifungal agents useful in therapy of systemic fungal infections. Annu. Rev. Pharmacol. Toxicol. 23:1983;303-330.
37. New R.R., Chance M.L., Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:1981;371-381.
38. Norman A.W., Spielvogel A.M., Wong R.G. Polyene antibiotic-sterol interaction. Adv. Lipid Res. 14:1976;127-170.
39. Otake T., Miyano K., Mori H., Morimoto M., Ueba N., Kunita N., Nakashima H., Kurimura T. Anti-HIV-1 activity of sulfated amphotericin B in vitro. Antiviral Res. 16:1991;243-266.
40. Pinter A., Chen T., Lowy A., Cortez N.G., Silagi S. Ecotropic murine leukemia virus-induced fusion of murine cells. J. Virol. 57:1986;1048-1054.
41. Pleskoff O., Seman M., Alizon M. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion. J. Virol. 69:1995;570-574.
42. Pleskoff O., Sol N., Marrakchi H., Serlin M., Seman M., Alizon M. Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry. J. Virol. 70:1996;8247-8251.
43. Pontani D.R., Sun D., Brown J.W., Shahied S.I., Plescia O.J., Schaffner C.P., Lopez-Berestein G., Sarin P.S. Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res. 11:1989;119-125.
44. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 224:1984;497-500.
45. Schaffner C.P., Plescia O.J., Pontani D., Sun D., Thornton A., Pandey R.C., Sarin P.S. Anti-viral activity of amphotericin B methyl ester: inhibition of HTLV-III replication in cell culture. Biochem. Pharmacol. 35:1986;4110-4113.
46. Schols D., Este J.A., Henson G., De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 35:1997;147-156.
47. Selvam M.P., Blay R.A., Geyer S., Buck S.M., Pollock L., Mayner R.E., Epstein J.S. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents. AIDS Res. Hum. Retroviruses. 9:1993;475-481.
48. Stevens N.M., Eagle C.A., Fisher P.B., Mechlinski W., Schaffner C.P. In vitro antiherpetic activity of water soluble amphotericin methyl ester. Arch. Virol. 48:1975;391-394.
49. Szoka F.C. Jr., Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:1987;421-429.
50. Torre-Cisneros J., Villanueva J.L., Kindelan J.M., Jurado R., Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 17:1994;625-627.
51. van Etten E.W.M., van Vianen W., Hak J., Bakker-Woudenberg I.A.J.M. Activity of liposomal Amphotericin B with prolonged circulation in blood vs. those of AmBisome and Fungizone against intracellular Candida albicans in murine peritoneal macrophages. Antimicrob. Agents Chemother. 42:1998;2437-2439.
52. Vasudevachari M.B., Battista C., Lane H.C., Psallidopoulos M.C., Zhao B., Cook J., Palmer J.R., Romero D.L., Tarpley W.G., Salzman N.P. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology. 190:1992;269-277.
53. Walsh T.J., Pizzo P.A. Treatment of systemic fungal infections: recent progress and current problems. Eur. J. Clin. Microbiol. Infect. Dis. 7:1988;460-475.
54. Wasan K.M., Lopez-Berestein G. Targeted liposomes in fungi: modifying the therapeutic index of Amphotericin B by its incorporation into negatively charged liposomes. J. Liposome Res. 5:1995;883-905.
55. White H., Anaissie E.J., Kusne S., Wingard J.R., Hiemenz J.W., Cantor A., Gurwith M., Du Mond C., Mamelok R.D., Bowden R.A. Amphotericin B colloidal dispersion vs. Amphotericin B as therapy for invasive aspergillosis. Cin. Infect. Dis. 24:1997;635-642.
56. Wiebe V.J., DeGregorio M.W. Liposome-encapsulated Amphotericin B: a promising new treatment for disseminated fungal infections. Rev. Infect. Dis. 10:1988;1097-1101.